 SAN FRANCISCO, Feb. 25, 2021 PRNewswire -- Kindred Biosciences, Inc. NASDAQ: KIN, a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States... 